Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Karyopharm Therapeutics Inc. (KPTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives"
12/13/2022 8-K Other Events  Interactive Data
12/05/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress"
07/28/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Transition Agreement, between the Company and Michael G. Kauffman",
"Transition Agreement, between the Company and Sharon Shacham"
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
02/08/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives"
12/21/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
12/08/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business"
08/05/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results"
06/24/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/18/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Karyopharm Announces FDA Approval of XPOVIO ® as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy"
12/17/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Second Amended and Restated By-Laws of Karyopharm Therapeutics Inc"
12/01/2020 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
11/02/2020 8-K Quarterly results
Docs: "Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress",
"Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma"
09/25/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy